OMG, oligodendrocyte myelin glycoprotein, 4974

N. diseases: 22; N. variants: 1
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0027831
Disease: Neurofibromatosis 1
Neurofibromatosis 1 		0.040 GeneticVariation disease BEFREE It is concluded that PPMS in patients with NF1 can occur without concurrent mutation of the OMgp gene. 10766898 2000
CUI: C0027831
Disease: Neurofibromatosis 1
Neurofibromatosis 1 		0.040 Biomarker disease BEFREE Quantitative analysis of NF1 and OMGP gene transcripts in sporadic gliomas, sporadic meningiomas and neurofibromatosis type 1-associated plexiform neurofibromas. 10378372 1999
CUI: C0027831
Disease: Neurofibromatosis 1
Neurofibromatosis 1 		0.040 GeneticVariation disease BEFREE The coincidence of neurofibromatosis 1 and multiple sclerosis might be due to a mutation in the embedded oligodendrocyte-myelin glycoprotein gene. 7745407 1995
CUI: C0027831
Disease: Neurofibromatosis 1
Neurofibromatosis 1 		0.040 Biomarker disease BEFREE Minimally, each of the deletions involved the entire 350-kb NF1 gene; the three genes--EVI2A, EVI2B, and OMG--that are contained within an NF1 intron; and considerable flanking DNA. 8116612 1994
CUI: C0751340
Disease: Myasthenia Gravis, Ocular
Myasthenia Gravis, Ocular 		0.030 Biomarker disease BEFREE It is unclear whether this benefit applies to patients with myasthenia and purely ocular manifestations (ocular myasthenia gravis [OMG]). 31453917 2020
CUI: C0751340
Disease: Myasthenia Gravis, Ocular
Myasthenia Gravis, Ocular 		0.030 Biomarker disease BEFREE Most patients first present with extraocular symptoms (diplopia and/or ptosis), and in 15% of cases symptoms will remain restricted to only the extraocular muscles (ocular myasthenia gravis [OMG]). 31847046 2019
CUI: C0751340
Disease: Myasthenia Gravis, Ocular
Myasthenia Gravis, Ocular 		0.030 GeneticVariation disease BEFREE Ocular myasthenia gravis (Ocular MG, OMG) shares many clinical features with thyroid-associated orbitopathy or thyroid-associated ophthalmopathy (TAO). 30809198 2018
CUI: C0026769
Disease: Multiple Sclerosis
Multiple Sclerosis 		0.030 Biomarker disease BEFREE Myelin-associated inhibitors, such as NogoA, myelin-associated glycoprotein (MAG), and oligodendrocyte myelin glycoprotein (OMgp), play a pivotal role in the lack of neuroregeneration in multiple sclerosis, an inflammatory demyelinating disease of the central nervous system (CNS). 27933584 2017
CUI: C0026769
Disease: Multiple Sclerosis
Multiple Sclerosis 		0.030 GeneticVariation disease BEFREE Results indicate that MAG, MBP, OMGP, and PLP genes do not have a significant genetic effect on susceptibility to MS in this population. 10541588 1999
CUI: C0026769
Disease: Multiple Sclerosis
Multiple Sclerosis 		0.030 GeneticVariation disease BEFREE We have examined two closely related genes present in the first intron of the neurofibromatosis type I gene--the oligodendrocyte myelin glycoprotein (OMGP) gene and the ecotropic viral integration 2A (EVI2A) gene--in 36 patients with multiple sclerosis (MS) and 36 healthy controls. 7477728 1995
CUI: C0005745
Disease: Blepharoptosis
Blepharoptosis 		0.020 GeneticVariation disease BEFREE Twenty-two patients with OMG presenting with isolated ptosis or diplopia, who initially tested negative, were re-tested in relation to a worsening of their symptoms showing a positivisation in 91% of cases. 31734908 2020
CUI: C0033377
Disease: Ptosis
Ptosis 		0.020 GeneticVariation disease BEFREE Twenty-two patients with OMG presenting with isolated ptosis or diplopia, who initially tested negative, were re-tested in relation to a worsening of their symptoms showing a positivisation in 91% of cases. 31734908 2020
CUI: C0005745
Disease: Blepharoptosis
Blepharoptosis 		0.020 Biomarker disease BEFREE Most patients first present with extraocular symptoms (diplopia and/or ptosis), and in 15% of cases symptoms will remain restricted to only the extraocular muscles (ocular myasthenia gravis [OMG]). 31847046 2019
CUI: C0033377
Disease: Ptosis
Ptosis 		0.020 Biomarker disease BEFREE Most patients first present with extraocular symptoms (diplopia and/or ptosis), and in 15% of cases symptoms will remain restricted to only the extraocular muscles (ocular myasthenia gravis [OMG]). 31847046 2019
CUI: C0206728
Disease: Plexiform Neurofibroma
Plexiform Neurofibroma 		0.020 Biomarker disease BEFREE Five genes were significantly upregulated: OMG and SUZ12 in plexiform neurofibromas and ATAD5, EVI2A and C17orf79 in MPNSTs. 20844836 2011
CUI: C0206728
Disease: Plexiform Neurofibroma
Plexiform Neurofibroma 		0.020 GeneticVariation disease BEFREE Quantitative analysis of NF1 and OMGP gene transcripts in sporadic gliomas, sporadic meningiomas and neurofibromatosis type 1-associated plexiform neurofibromas. 10378372 1999
CUI: C0947912
Disease: Myasthenias
Myasthenias 		0.010 Biomarker disease BEFREE It is unclear whether this benefit applies to patients with myasthenia and purely ocular manifestations (ocular myasthenia gravis [OMG]). 31453917 2020
CUI: C0006118
Disease: Brain Neoplasms
Brain Neoplasms 		0.010 Biomarker group BEFREE In view of its suggested low toxicity and transport properties across the BBB, 3-OMG provides an option to be used as a nonmetallic contrast agent for evaluating brain tumors. 30206994 2019
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.010 Biomarker group BEFREE Dynamic 3-OMG weighted images were collected using CEST-MRI at 11.7 T at a single offset of 1.2 ppm, showing the effect of accumulation of the contrast agent in the tumor, following an intravenous injection of 3-OMG (3 g/kg). 30206994 2019
CUI: C0040021
Disease: Thromboangiitis Obliterans
Thromboangiitis Obliterans 		0.010 Biomarker disease BEFREE Ocular myasthenia gravis (Ocular MG, OMG) shares many clinical features with thyroid-associated orbitopathy or thyroid-associated ophthalmopathy (TAO). 30809198 2018
CUI: C0339143
Disease: Thyroid associated opthalmopathies
Thyroid associated opthalmopathies 		0.010 Biomarker disease BEFREE Ocular myasthenia gravis (Ocular MG, OMG) shares many clinical features with thyroid-associated orbitopathy or thyroid-associated ophthalmopathy (TAO). 30809198 2018
CUI: C0011303
Disease: Demyelinating Diseases
Demyelinating Diseases 		0.010 Biomarker group BEFREE Myelin-associated inhibitors, such as NogoA, myelin-associated glycoprotein (MAG), and oligodendrocyte myelin glycoprotein (OMgp), play a pivotal role in the lack of neuroregeneration in multiple sclerosis, an inflammatory demyelinating disease of the central nervous system (CNS). 27933584 2017
CUI: C0011860
Disease: Diabetes Mellitus, Non-Insulin-Dependent
Diabetes Mellitus, Non-Insulin-Dependent 		0.010 Biomarker disease BEFREE We evaluated the effects of metformin on serum 3-O-methylglucose (3-OMG; a marker of glucose absorption) and plasma total GLP-1 concentrations during a standardized intraduodenal infusion of glucose and 3-OMG in patients with type 2 diabetes. 27761984 2017
CUI: C0740391
Disease: Middle Cerebral Artery Occlusion
Middle Cerebral Artery Occlusion 		0.010 Biomarker disease BEFREE The protein levels of the myelin-derived growth inhibitory proteins, neurite growth inhibitor-A (Nogo-A), myelin-associated glycoprotein (MAG) and oligodendrocyte-myelin glycoprotein (OMG) were also examined by Western blot after MCAO. 28413924 2017
CUI: C0028754
Disease: Obesity
Obesity 		0.010 Biomarker disease BEFREE Peak plasma 3-OMG in both RYGB (r = 0.69, P = 0.01) and obese (r = 0.72, P = 0.005) correlated with baseline expression of SGLT-1, as was the case with peak blood glucose in RYGB subjects (r = 0.69, P = 0.02). 24990218 2014